Biogen

Historical price data

Biogen stands as a premier biotechnology company focused on developing innovative therapies for complex neurological, immunological, and rare diseases with significant unmet medical needs. With decades of pioneering work in multiple sclerosis and recent expansions into nephrology through the acquisition of Human Immunology Biosciences, the company maintains a diverse pipeline spanning Alzheimer's disease, ALS, lupus, and other challenging conditions. Biogen's commitment to scientific excellence is demonstrated through substantial annual R&D investment of $2 billion and a global team of over 1,300 research professionals driving innovation from discovery to commercialization.

Biogen leverages deep understanding of human disease biology combined with diverse therapeutic modalities including antisense oligonucleotides, monoclonal antibodies, and novel approaches to neurodegeneration and immune-mediated diseases.

529 drugs in pipeline, 101 in Phase 3

Total raised: $750M

Biogen competes with major pharmaceutical companies including Roche/Genentech in neurology, Novartis in rare diseases, and numerous biotech companies across its therapeutic focus areas. The company differentiates through its 25+ years of neurology expertise, particularly in multiple sclerosis, established commercial infrastructure, and deep relationships with specialist physicians in complex therapeutic areas.